KR100414587B1 - 페닐아세테이트 및 페닐아세틸글루타민을 포함하는약제학적 조성물 - Google Patents

페닐아세테이트 및 페닐아세틸글루타민을 포함하는약제학적 조성물 Download PDF

Info

Publication number
KR100414587B1
KR100414587B1 KR10-2003-7002798A KR20037002798A KR100414587B1 KR 100414587 B1 KR100414587 B1 KR 100414587B1 KR 20037002798 A KR20037002798 A KR 20037002798A KR 100414587 B1 KR100414587 B1 KR 100414587B1
Authority
KR
South Korea
Prior art keywords
formula
compound
patients
day
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR10-2003-7002798A
Other languages
English (en)
Korean (ko)
Other versions
KR20030027087A (ko
Inventor
스탠니슬로우 알. 벌진스키
Original Assignee
벌진스키, 스탠니슬로우, 알
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 벌진스키, 스탠니슬로우, 알 filed Critical 벌진스키, 스탠니슬로우, 알
Publication of KR20030027087A publication Critical patent/KR20030027087A/ko
Application granted granted Critical
Publication of KR100414587B1 publication Critical patent/KR100414587B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
KR10-2003-7002798A 1998-07-23 1999-07-02 페닐아세테이트 및 페닐아세틸글루타민을 포함하는약제학적 조성물 Expired - Fee Related KR100414587B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/121,567 1998-07-23
US09/121,567 US6258849B1 (en) 1998-07-23 1998-07-23 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
PCT/US1999/015017 WO2000004894A2 (en) 1998-07-23 1999-07-02 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR10-2001-7001021A Division KR100399658B1 (ko) 1998-07-23 1999-07-02 페닐아세틸글루타민 및 페닐아세틸이소글루타민을 포함하는 약제학적 조성물

Publications (2)

Publication Number Publication Date
KR20030027087A KR20030027087A (ko) 2003-04-03
KR100414587B1 true KR100414587B1 (ko) 2004-01-13

Family

ID=22397538

Family Applications (4)

Application Number Title Priority Date Filing Date
KR10-2003-7002798A Expired - Fee Related KR100414587B1 (ko) 1998-07-23 1999-07-02 페닐아세테이트 및 페닐아세틸글루타민을 포함하는약제학적 조성물
KR10-2001-7001021A Expired - Fee Related KR100399658B1 (ko) 1998-07-23 1999-07-02 페닐아세틸글루타민 및 페닐아세틸이소글루타민을 포함하는 약제학적 조성물
KR10-2003-7002800A Expired - Fee Related KR100417101B1 (ko) 1998-07-23 1999-07-02 페닐아세테이트의 수성용액을 포함하는 약제학적 조성물
KR10-2003-7002799A Expired - Fee Related KR100417100B1 (ko) 1998-07-23 1999-07-02 페닐아세테이트 및 페닐아세틸이소글루타민을 포함하는약제학적 조성물

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR10-2001-7001021A Expired - Fee Related KR100399658B1 (ko) 1998-07-23 1999-07-02 페닐아세틸글루타민 및 페닐아세틸이소글루타민을 포함하는 약제학적 조성물
KR10-2003-7002800A Expired - Fee Related KR100417101B1 (ko) 1998-07-23 1999-07-02 페닐아세테이트의 수성용액을 포함하는 약제학적 조성물
KR10-2003-7002799A Expired - Fee Related KR100417100B1 (ko) 1998-07-23 1999-07-02 페닐아세테이트 및 페닐아세틸이소글루타민을 포함하는약제학적 조성물

Country Status (20)

Country Link
US (2) US6258849B1 (enExample)
EP (1) EP1098643B1 (enExample)
JP (2) JP2002521329A (enExample)
KR (4) KR100414587B1 (enExample)
CN (3) CN1605334A (enExample)
AT (1) ATE257378T1 (enExample)
AU (1) AU759278B2 (enExample)
BR (1) BR9912356A (enExample)
CA (1) CA2336945C (enExample)
DE (1) DE69914084T2 (enExample)
DK (1) DK1098643T3 (enExample)
EA (1) EA004179B1 (enExample)
ES (1) ES2214866T3 (enExample)
ID (1) ID28160A (enExample)
IL (1) IL140848A (enExample)
NZ (1) NZ509244A (enExample)
PL (1) PL213698B1 (enExample)
PT (1) PT1098643E (enExample)
WO (1) WO2000004894A2 (enExample)
ZA (1) ZA200100622B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127419A (en) * 1998-11-23 2000-10-03 Burzynski; Stanislaw R. Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis
ATE311358T1 (de) * 2000-08-29 2005-12-15 Nobex Corp Immunoregulierende verbindungen, deren derivate und ihre verwendung
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US7087219B2 (en) * 2003-05-28 2006-08-08 Stanislaw R. Burzynski Toothpaste containing anticancer agents
US20060246016A1 (en) * 2003-05-28 2006-11-02 Burzynski Stanislaw R Toothpaste containing anticancer agents
US7772108B2 (en) * 2004-06-25 2010-08-10 Samsung Electronics Co., Ltd. Interconnection structures for semiconductor devices and methods of forming the same
PL1773767T3 (pl) 2004-07-07 2016-07-29 Biocon Ltd Synteza azowo związanych związków immunoregulacyjnych
CA2575367A1 (en) * 2004-07-28 2006-02-23 Board Of Regents, The University Of Texas System 3-halo-2-oxopropionate salts and esters as novel anticancer agents
PT2319581E (pt) 2004-11-26 2015-06-30 Ucl Business Plc Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática
US20060205818A1 (en) * 2005-03-08 2006-09-14 Burzynski Stanislaw R Method for the treatment of von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives
CN106810464B (zh) 2009-04-03 2019-01-22 欧塞拉治疗有限公司 L-鸟氨酸苯乙酸盐及其制备方法
ES2517340T3 (es) 2009-06-08 2014-11-03 Ucl Business Plc Tratamiento de la hipertensión portal usando L-ornitina y fenilacetato
EP2625162B1 (en) 2010-10-06 2019-03-13 Ocera Therapeutics, Inc. Methods of making l-ornithine phenyl acetate
KR20230018526A (ko) 2014-11-24 2023-02-07 유씨엘 비즈니스 리미티드 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료
JP6990170B2 (ja) 2015-08-18 2022-01-12 オセラ セラピューティクス， インコーポレイテッド Ｌ－オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも１つと組み合わせて用いる筋肉喪失の治療および予防
EP3397960B1 (en) * 2015-12-30 2020-01-29 Société des Produits Nestlé S.A. Method for determining fat free body mass
US10624869B2 (en) * 2017-05-08 2020-04-21 Stanislaw R. Burzynski Methods for the treatment of recurrent glioblastoma (RGBM)
MX389665B (es) 2017-05-11 2025-03-20 Ocera Therapeutics Inc Procesos para producir fenilacetato de l-ornitina
EA202090024A1 (ru) * 2017-06-12 2020-04-10 Станислав Р. Бурзинский Способы лечения лептоменингеального заболевания
US11344521B2 (en) 2017-06-12 2022-05-31 Burzynski Research Institute, Inc. Methods for the treatment of leptomeningeal disease
US20230190694A1 (en) * 2021-11-03 2023-06-22 Stanislaw R. Burzynski Compositions for and methods of precision cancer treatment
CN116019798B (zh) * 2022-07-20 2024-03-12 中南大学湘雅二医院 苯乙酰谷氨酰胺在制备预防和/或治疗阿霉素所致心脏毒性的药物中的应用
CN116491472B (zh) * 2022-12-14 2024-07-26 上海交通大学医学院附属第九人民医院 苯乙酰谷氨酰胺在构建慢性创面动物模型中的用途
WO2024263966A2 (en) * 2023-06-21 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating pancreatic cancer
WO2024263963A2 (en) * 2023-06-21 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating head and neck cancer
EP4731792A2 (en) * 2023-06-21 2026-04-29 Stanislaw R. Burzynski Compositions comprising antineoplastons and methods of treating lung cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4470970A (en) 1981-07-02 1984-09-11 Burzynski Stanislaw R Purified antineoplaston fractions and methods of treating neoplastic disease
US5254587A (en) 1990-09-04 1993-10-19 Burzynski Stanislaw R Methods for treating AIDS
US5244922A (en) * 1990-09-04 1993-09-14 Burzynski Stanislaw R Methods for treating viral infections
US5605930A (en) 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
DE69734713T2 (de) 1996-05-14 2006-07-06 Burzynski, Stanislaw R., Houston Liposomale antineoplaston therapie mit bemerkenswert verbesserter antineoplastischer aktivität

Also Published As

Publication number Publication date
KR100417101B1 (ko) 2004-02-05
KR20010071025A (ko) 2001-07-28
EP1098643B1 (en) 2004-01-07
ZA200100622B (en) 2002-06-26
ID28160A (id) 2001-05-10
US6943192B2 (en) 2005-09-13
US20010044466A1 (en) 2001-11-22
EP1098643A2 (en) 2001-05-16
WO2000004894A3 (en) 2000-04-27
DK1098643T3 (da) 2004-05-24
NZ509244A (en) 2004-02-27
KR20030027087A (ko) 2003-04-03
AU4854299A (en) 2000-02-14
PL213698B1 (pl) 2013-04-30
US6258849B1 (en) 2001-07-10
BR9912356A (pt) 2001-04-17
CN1605334A (zh) 2005-04-13
WO2000004894A2 (en) 2000-02-03
KR100417100B1 (ko) 2004-02-05
IL140848A0 (en) 2002-02-10
EA200100168A1 (ru) 2001-08-27
DE69914084D1 (de) 2004-02-12
KR20030027089A (ko) 2003-04-03
CA2336945A1 (en) 2000-02-03
CN1660061A (zh) 2005-08-31
CN1319010A (zh) 2001-10-24
CA2336945C (en) 2008-11-18
KR100399658B1 (ko) 2003-09-29
DE69914084T2 (de) 2004-10-28
EA004179B1 (ru) 2004-02-26
PT1098643E (pt) 2004-05-31
KR20030027088A (ko) 2003-04-03
JP2011051993A (ja) 2011-03-17
CN1191064C (zh) 2005-03-02
ATE257378T1 (de) 2004-01-15
PL345959A1 (en) 2002-01-14
ES2214866T3 (es) 2004-09-16
JP2002521329A (ja) 2002-07-16
AU759278B2 (en) 2003-04-10
CN100400039C (zh) 2008-07-09
IL140848A (en) 2005-05-17
HK1037142A1 (en) 2002-02-01

Similar Documents

Publication Publication Date Title
KR100417100B1 (ko) 페닐아세테이트 및 페닐아세틸이소글루타민을 포함하는약제학적 조성물
EP1066830B1 (en) Uses and compositions for treating primary and secondary tumors of the central nervous system (cns)
KR19980064024A (ko) 약학 조성물
KR20040065565A (ko) 세포독성 화학요법의 독성효과 감소에 유용한 아미노산 및리보플라빈 조성물
CA2343120C (en) Use of an anthracycline derivative for the treatment of a liver tumor
HK1037142B (en) Phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate for the treatment of neoplastic diseases
US7226766B2 (en) S-methylcysteine, S-ethylcysteine, and related S-alkylthiols as antagonists to the effects of S-nitrosothiols and nitric oxide
PH26099A (en) Method for preparing 3-(N-phenylacetyl-aminopiperidine) 2,6-dion
MXPA99000255A (en) Treatment regimen for the administration of phenylacetilglutamine, phenylacetilisoglutamine and / or fen acetate
US20060148885A1 (en) Medicinal composition
KR20010027403A (ko) 구연산칼륨을 주제로 한 요로결석치료제의 제조방법
HK1074771A (en) Use of composition in the manufacture of a medicament for treating neoplastic disease

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

Fee payment year number: 4

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 5

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 6

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 7

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 8

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 9

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20121210

Year of fee payment: 10

PR1001 Payment of annual fee

Fee payment year number: 10

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20131210

Year of fee payment: 11

PR1001 Payment of annual fee

Fee payment year number: 11

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20141209

Year of fee payment: 12

PR1001 Payment of annual fee

Fee payment year number: 12

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20160303

Year of fee payment: 13

PR1001 Payment of annual fee

Fee payment year number: 13

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20170103

Year of fee payment: 14

PR1001 Payment of annual fee

Fee payment year number: 14

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20171212

Year of fee payment: 15

PR1001 Payment of annual fee

Fee payment year number: 15

St.27 status event code: A-4-4-U10-U11-oth-PR1001

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Not in force date: 20181227

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20181227

St.27 status event code: N-4-6-H10-H13-oth-PC1903